MedPath

Polyneuron Pharmaceuticals AG

Polyneuron Pharmaceuticals AG logo
🇨🇭Switzerland
Ownership
Holding
Established
2014-01-01
Employees
1
Market Cap
-
Website
http://www.polyneuron.com

Clinical Trials

4

Active:2
Completed:1

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (100.0%)

First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy

Phase 1
Terminated
Conditions
Anti-MAG Neuropathy
Interventions
Drug: Placebo
First Posted Date
2020-09-29
Last Posted Date
2021-10-15
Lead Sponsor
Polyneuron Pharmaceuticals AG
Target Recruit Count
1
Registration Number
NCT04568174
Locations
🇫🇷

Service de Neurologie Centre de Référence Neuropathies Périphériques Rares, CHU Limoges, Limoges, France

🇫🇷

Referral centre for neuromuscular diseases and ALS, hôpital La Timone, Marseille, France

🇫🇷

Département de Neurologie Pôle Neurosciences Centre de Référence des Neuropathies Amyloïdes Familiales et autres Neuropathies Périphériques Rares Centre Hospitalier Universitaire de Bicêtre, Paris, France

and more 4 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.